Related Experiment Videos
Metaproterenol (Alupent) metered dose inhaler in children 5-12 years of age
Insights
Metaproterenol sulfate inhalers effectively improved lung function in children aged 5-12 with asthma. This study found the medication safe and beneficial for pediatric asthma treatment.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Asthma is a common chronic respiratory disease in children.
- Metered-dose inhalers are a standard delivery method for asthma medications.
- Evaluating the efficacy and safety of bronchodilators in pediatric populations is crucial.
Purpose of the Study:
- To assess the safety and efficacy of metaproterenol sulfate (Alupent) metered dose inhaler.
- To evaluate its impact on pulmonary function in children with asthma aged 5 to 12 years.
Main Methods:
- A multiclinic, randomized, placebo-controlled study.
- 268 children (ages 5-12) received metaproterenol or placebo for 30 days.
- Spirometric testing (FEV1, FEF25-75%) conducted pre- and post-dose on Days 1 and 30.
Main Results:
- Metaproterenol demonstrated statistically significant superiority over placebo in improving pulmonary function parameters.
- Significant improvements observed in FEV1 and FEF25-75% peak values and area under the curve.
- No significant adverse side effects were reported during the study period.
Conclusions:
- Metaproterenol sulfate metered dose inhaler is a safe and effective treatment option for pediatric asthma.
- The medication provides significant bronchodilatory effects in children aged 5 to 12 years.
- Supports the use of metaproterenol for managing asthma in this age group.
Abstract:
This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent) metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.